Analystreport

Celldex Therapeutics (CLDX) was upgraded by Barclays PLC from "underweight" to "overweight". They now have a $45.00 price target on the stock.

Celldex Therapeutics, Inc.  (CLDX) 
Last celldex therapeutics, inc. earnings: 11/12 08:01 am Check Earnings Report
US:NASDAQ Investor Relations: ir.celldex.com